Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2023 · 10-Q
Revenue$164.30M$164.30M−46.1% vs Q1 2022 Net Income-$186.20M-$186.20MN/M vs Q1 2022 EPS Diluted-$3.71-$3.71N/M vs Q1 2022 Gross Profit$4,900,000−96.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow-$184,000,000N/M Free Cash Flowderived-$199,100,000N/M Margins · derivedGross margin3.0%−43.6 pt vs Q1 2022
Operating margin-89.8%−92.1 pt vs Q1 2022
Net margin-113.3%−111.8 pt vs Q1 2022
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end